Optical Coherence Tomography-Based Choroidal Structural Analysis and Vascularity Index in Best Vitelliform Macular Dystrophy.
Best vitelliform macular dystrophy
Choroid
Choroidal structural analysis
Choroidal vascularity index
Optical coherence tomography
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
01
07
2022
accepted:
26
08
2022
pubmed:
25
9
2022
medline:
25
9
2022
entrez:
24
9
2022
Statut:
ppublish
Résumé
This study investigated choroidal structural changes on optical coherence tomography (OCT) using choroidal vascularity index (CVI) and choroidal thickness (CT) in patients with Best vitelliform macular dystrophy (BVMD). This retrospective case control study included 78 patients with BVMD of different clinical stages and 242 age- and gender-matched healthy controls. Subfoveal OCT scans were analysed. Total choroidal area (TCA), luminal area (LA) and CT were measured after image segmentation and binarization. CVI, a novel marker for choroidal angioarchitecture, was defined as the ratio of LA to TCA. CVI and CT were compared between BVMD and control group, as well as among the BVMD subgroups. Mean CVI was lower in eyes with BVMD (65.0 ± 3.5%) compared to that in control eyes (67.5 ± 3.9%) and this was statistically significant (p < 0.0001). There was no significant difference in subfoveal CT between BVMD (302.88 ± 81.68 μm) and control (309.31 ± 65.46 μm) eyes (p = 0.4799). In the subgroup analysis, all stages of BVMD showed lower CVI compared to control while SFCT remained similar. Within the BVMD subgroups, CVI and subfoveal CT did not differ significantly and both were not shown to be associated with visual acuity. Decreased CVI was shown in eyes with BVMD compared to control eyes, while no significant difference in subfoveal CT was seen. CVI may be helpful in the understanding of choroidal pathology in BVMD.
Identifiants
pubmed: 36153433
doi: 10.1007/s40123-022-00567-y
pii: 10.1007/s40123-022-00567-y
pmc: PMC9587204
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2141-2152Informations de copyright
© 2022. The Author(s).
Références
Prog Retin Eye Res. 1998 Apr;17(2):175-205
pubmed: 9695792
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1986-93
pubmed: 12037009
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12758-63
pubmed: 11050159
Graefes Arch Clin Exp Ophthalmol. 2010 Dec;248(12):1719-28
pubmed: 20640437
Prog Retin Eye Res. 2017 May;58:70-88
pubmed: 28111324
Ophthalmic Genet. 2017 Mar-Apr;38(2):143-147
pubmed: 27120116
Retina. 2016 Apr;36(4):764-9
pubmed: 26447398
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):61
pubmed: 32602906
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):358-63
pubmed: 18172113
Prog Retin Eye Res. 2009 May;28(3):187-205
pubmed: 19375515
Ophthalmic Genet. 2017 Jan-Feb;38(1):79-82
pubmed: 27031371
PLoS One. 2016 Jan 11;11(1):e0146344
pubmed: 26751702
Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):191-197
pubmed: 29554387
Indian J Ophthalmol. 2015 May;63(5):391-3
pubmed: 26139798
Ophthalmologica. 2018;240(1):45-54
pubmed: 29694963
Turk J Ophthalmol. 2019 Sep 03;49(4):226-229
pubmed: 31486612
Invest Ophthalmol Vis Sci. 2014 Jun 03;55(6):3893-9
pubmed: 24894395
Am J Ophthalmol. 2008 Oct;146(4):496-500
pubmed: 18639219
Acta Ophthalmol. 2019 Feb;97(1):e116-e121
pubmed: 30178525
Prog Retin Eye Res. 2020 Jul;77:100829
pubmed: 31927136
Nat Genet. 1998 Jul;19(3):241-7
pubmed: 9662395
Retina. 2018 Dec;38(12):2395-2400
pubmed: 29016459
Retina. 2012 Jan;32(1):25-31
pubmed: 21878837
Sci Rep. 2016 Feb 12;6:21090
pubmed: 26868048
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18751-6
pubmed: 19841260
Prog Retin Eye Res. 2017 May;58:45-69
pubmed: 28153808
Acta Ophthalmol. 2017 Nov;95(7):e597-e601
pubmed: 28391615
Am J Ophthalmol. 2012 Aug;154(2):403-412.e4
pubmed: 22633354
Retina. 2017 Jun;37(6):1120-1125
pubmed: 27632714
Arch Ophthalmol. 1982 Jul;100(7):1115-21
pubmed: 7092655